BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 16, 2001
View Archived Issues
U.S. FDA reviews sample of new drugs approved last year
Read More
SuperGen obtains certain rights to VTA technology
Read More
Q2 2001 at Neurochem marked by completion of proof-of-concept study for AD compound
Read More
Maxim receives SBIR grants for evaluation of anticancer agents
Read More
Long-acting contraceptive launched by Berlex in U.S.
Read More
Genzyme Transgenics to produce Atlantic's ABI-001
Read More
Blockade of alpha4 integrin provides significant neuroprotection in animal models of stroke
Read More
Okayama University scientists investigate role of PARP in post-SAH cerebral vasospasm
Read More
Neuroprotection provided by new antioxidant manganese complexes
Read More
Merck's new oligopeptide-cytotoxic agent conjugates useful for Rx of cancer, BPH
Read More
New therapeutic option for allergies available from UCB in Germany
Read More
Joint research at Ortho-McNeil and Cor leads to new peptoid/peptidomimetic PAR-1 antagonists
Read More
Pyrimidine-based protein tyrosine kinase inhibitors and their use described by Merck
Read More
Bayer patents new series of potassium channel blockers especially for dementia and depression
Read More
Triazole and imidazole derivatives from Roche are NMDA subtype-selective blockers
Read More
Antagonists at 5-HT2B/5-HT2C receptors designed at ADIR
Read More
Toleragen candidate for APS reduces disease-causing antibodies, corrects clotting defect in animals
Read More
IGT Pharma/Neurotrophic Bioscience merger nears completion
Read More
Teva finalizes separate agreements with Aventis and Lundbeck
Read More
Patient enrollment complete in phase IIb trial of IL-2 gene medicine for H&N cancer
Read More
FDA advisory committee recommends approval of injectable ziprasidone
Read More
TOPAS trial evaluates different doses of certoparin in acute ischemic stroke patients
Read More
Questcor licenses novel antifungal technology to Tularik
Read More
SIGA Technologies reports clinical trial results for vaccine delivery technology
Read More
GenVec begins phase I clinical trial with TNFerade
Read More
Melacine now available in Canada for treatment of stage IV melanoma
Read More